More than 1,200 clinical trials across the world faced some kind of disruption due to the Covid-19 outbreak.

The most common disruptions were slow enrolment, suspension of registration and delayed initiation of trials.

According to GlobalData, the number of disrupted trials peaked in June 2020, following which the figure declined marginally.

Covid-19 pandemic disrupted more than 1,200 clinical trialsClinical Trials that Have Been Disrupted

However, clinical trials affected by slow enrolment were steadily increasing, as of 27 July 2020.

Overall, around 50% of the clinical trials were impacted due to enrolment suspension amid the pandemic. Slow enrolment and delayed initiation accounted for 33% and 17% of the disruptions, respectively.

The information is based on GlobalData’s Pharmaceutical Intelligence Centre and Clinical Trials Database.